ASH 2019 | First-in-human study of TAK-169 in R/R MM
Shaji Kumar
• 7 Dec 2019
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the ongoing, first-in-human, phase I study (NCT04017130) of TAK-169, a dimeric fusion protein of an anti-CD38 antibody single chain variable fragment fused to a modified Shiga-like toxin-A subunit. This study comprises dose escalation and expansion, and will assess the safety and tolerability of TAK-169 in relapsed/refractory multiple myeloma (MM) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
